Literature DB >> 29343568

An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor.

Amanda M Dudek1,2,3, Sirika Pillay4, Andreas S Puschnik4, Claude M Nagamine5, Fang Cheng6, Jianming Qiu6, Jan E Carette4, Luk H Vandenberghe7,2,3,8.   

Abstract

Determinants and mechanisms of cell attachment and entry steer adeno-associated virus (AAV) in its utility as a gene therapy vector. Thus far, a systematic assessment of how diverse AAV serotypes engage their proteinaceous receptor AAVR (KIAA0319L) to establish transduction has been lacking, despite potential implications for cell and tissue tropism. Here, a large set of human and simian AAVs as well as in silico-reconstructed ancestral AAV capsids were interrogated for AAVR usage. We identified a distinct AAV capsid lineage comprised of AAV4 and AAVrh32.33 that can bind and transduce cells in the absence of AAVR, independent of the multiplicity of infection. Virus overlay assays and rescue experiments in nonpermissive cells demonstrate that these AAVs are unable to bind to or use the AAVR protein for entry. Further evidence for a distinct entry pathway was observed in vivo, as AAVR knockout mice were equally as permissive to transduction by AAVrh32.33 as wild-type mice upon systemic injection. We interestingly observe that some AAV capsids undergo a low level of transduction in the absence of AAVR, both in vitro and in vivo, suggesting that some capsids may have a multimodal entry pathway. In aggregate, our results demonstrate that AAVR usage is conserved among all primate AAVs except for those of the AAV4 lineage, and a non-AAVR pathway may be available to other serotypes. This work furthers our understanding of the entry of AAV, a vector system of broad utility in gene therapy.IMPORTANCE Adeno-associated virus (AAV) is a nonpathogenic virus that is used as a vehicle for gene delivery. Here, we have identified several situations in which transduction is retained in both cell lines and a mouse model in the absence of a previously defined entry receptor, AAVR. Defining the molecular determinants of the infectious pathway of this highly relevant viral vector system can help refine future applications and therapies with this vector.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  AAV; adeno-associated virus; attachment; gene therapy; vector; viral entry; viral gene transfer; virus; virus receptor

Mesh:

Substances:

Year:  2018        PMID: 29343568      PMCID: PMC5972900          DOI: 10.1128/JVI.02213-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis.

Authors:  S Uhrig; O Coutelle; T Wiehe; L Perabo; M Hallek; H Büning
Journal:  Gene Ther       Date:  2011-06-09       Impact factor: 5.250

2.  AAVR: A Multi-Serotype Receptor for AAV.

Authors:  Candace Summerford; Jarrod S Johnson; R Jude Samulski
Journal:  Mol Ther       Date:  2016-04       Impact factor: 11.454

3.  The interaction of heparin sulfate and adeno-associated virus 2.

Authors:  J Qiu; A Handa; M Kirby; K E Brown
Journal:  Virology       Date:  2000-03-30       Impact factor: 3.616

4.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.

Authors:  Oliver J Müller; Barbara Leuchs; Sven T Pleger; Dirk Grimm; Wolfgang-M Franz; Hugo A Katus; Jürgen A Kleinschmidt
Journal:  Cardiovasc Res       Date:  2006-01-31       Impact factor: 10.787

6.  A new bioinformatics analysis tools framework at EMBL-EBI.

Authors:  Mickael Goujon; Hamish McWilliam; Weizhong Li; Franck Valentin; Silvano Squizzato; Juri Paern; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2010-05-03       Impact factor: 16.971

7.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

Authors:  Albert M Maguire; Katherine A High; Alberto Auricchio; J Fraser Wright; Eric A Pierce; Francesco Testa; Federico Mingozzi; Jeannette L Bennicelli; Gui-shuang Ying; Settimio Rossi; Ann Fulton; Kathleen A Marshall; Sandro Banfi; Daniel C Chung; Jessica I W Morgan; Bernd Hauck; Olga Zelenaia; Xiaosong Zhu; Leslie Raffini; Frauke Coppieters; Elfride De Baere; Kenneth S Shindler; Nicholas J Volpe; Enrico M Surace; Carmela Acerra; Arkady Lyubarsky; T Michael Redmond; Edwin Stone; Junwei Sun; Jennifer Wellman McDonnell; Bart P Leroy; Francesca Simonelli; Jean Bennett
Journal:  Lancet       Date:  2009-10-23       Impact factor: 79.321

8.  In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.

Authors:  Deniz Dalkara; Leah C Byrne; Ryan R Klimczak; Meike Visel; Lu Yin; William H Merigan; John G Flannery; David V Schaffer
Journal:  Sci Transl Med       Date:  2013-06-12       Impact factor: 17.956

9.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

10.  Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.

Authors:  Francesca Simonelli; Albert M Maguire; Francesco Testa; Eric A Pierce; Federico Mingozzi; Jeannette L Bennicelli; Settimio Rossi; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; T Michael Redmond; Xiaosong Zhu; Kenneth S Shindler; Gui-Shuang Ying; Carmela Ziviello; Carmela Acerra; J Fraser Wright; Jennifer Wellman McDonnell; Katherine A High; Jean Bennett; Alberto Auricchio
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more
  34 in total

1.  Polarized AAVR expression determines infectivity by AAV gene therapy vectors.

Authors:  Bradley A Hamilton; Xiaopeng Li; Alejandro A Pezzulo; Mahmoud H Abou Alaiwa; Joseph Zabner
Journal:  Gene Ther       Date:  2019-04-08       Impact factor: 5.250

Review 2.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

3.  Programmable Assembly of Adeno-Associated Virus-Antibody Composites for Receptor-Mediated Gene Delivery.

Authors:  Alina C Zdechlik; Yungui He; Eric J Aird; Wendy R Gordon; Daniel Schmidt
Journal:  Bioconjug Chem       Date:  2019-12-20       Impact factor: 4.774

4.  A CRISPR Screen Identifies the Cell Polarity Determinant Crumbs 3 as an Adeno-associated Virus Restriction Factor in Hepatocytes.

Authors:  Victoria J Madigan; Tyne O Tyson; Julianne A Yuziuk; Minakshi Pillai; Sven Moller-Tank; Aravind Asokan
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

5.  Structural Study of Aavrh.10 Receptor and Antibody Interactions.

Authors:  Mario Mietzsch; Jennifer C Yu; Jane Hsi; Paul Chipman; Felix Broecker; Zhang Fuming; Robert J Linhardt; Peter H Seeberger; Regine Heilbronn; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2021-09-22       Impact factor: 5.103

Review 6.  Cryo-electron Microscopy of Adeno-associated Virus.

Authors:  Scott M Stagg; Craig Yoshioka; Omar Davulcu; Michael S Chapman
Journal:  Chem Rev       Date:  2022-05-16       Impact factor: 72.087

7.  GPR108 Is a Highly Conserved AAV Entry Factor.

Authors:  Amanda M Dudek; Nerea Zabaleta; Eric Zinn; Sirika Pillay; James Zengel; Caryn Porter; Jennifer Santos Franceschini; Reynette Estelien; Jan E Carette; Guo Ling Zhou; Luk H Vandenberghe
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

8.  Cross-Packaging and Capsid Mosaic Formation in Multiplexed AAV Libraries.

Authors:  Pauline F Schmit; Simon Pacouret; Eric Zinn; Elizabeth Telford; Fotini Nicolaou; Frédéric Broucque; Eva Andres-Mateos; Ru Xiao; Magalie Penaud-Budloo; Mohammed Bouzelha; Nicolas Jaulin; Oumeya Adjali; Eduard Ayuso; Luk H Vandenberghe
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-26       Impact factor: 6.698

9.  Expression and Purification of Adeno-associated Virus Virus-like Particles in a Baculovirus System and AAVR Ectodomain Constructs in E. coli.

Authors:  Nancy Meyer; Omar Davulcu; Qing Xie; Mark Silveria; Grant M Zane; Edward Large; Michael S Chapman
Journal:  Bio Protoc       Date:  2020-02-05

10.  Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species.

Authors:  Mohammadsharif Tabebordbar; Kim A Lagerborg; Alexandra Stanton; Emily M King; Simon Ye; Liana Tellez; Allison Krunnfusz; Sahar Tavakoli; Jeffrey J Widrick; Kathleen A Messemer; Emily C Troiano; Behzad Moghadaszadeh; Bryan L Peacker; Krystynne A Leacock; Naftali Horwitz; Alan H Beggs; Amy J Wagers; Pardis C Sabeti
Journal:  Cell       Date:  2021-09-09       Impact factor: 66.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.